UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

International journal of hematology, 2023-03, Vol.117 (3), p.388-397

2023

Volltextzugriff (PDF)

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

Haematologica (Roma), 2010-01, Vol.95 (1), p.87-95

2010

Volltextzugriff (PDF)

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Haematologica (Roma), 2015-08, Vol.100 (8), p.1096

2015

Volltextzugriff (PDF)

Is Early Palliative Care Feasible in Patients With Multiple Myeloma?

Journal of pain and symptom management, 2017-11, Vol.54 (5), p.692-700

2017

Volltextzugriff (PDF)

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Leukemia & lymphoma, 2016-01, Vol.57 (1), p.86-91

2016

Volltextzugriff (PDF)

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Annals of hematology, 2021-07, Vol.100 (7), p.1769-1778

2021

Volltextzugriff (PDF)

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in immunology, 2024-02, Vol.15, p.1252445-1252445

2024

Volltextzugriff (PDF)

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in immunology, 2023-04, Vol.14, p.1158105-1158105

2023

Volltextzugriff (PDF)

Renal involvement in non-malignant IgM gammopathy

Nephrology, dialysis, transplantation, 2007-02, Vol.22 (2), p.627-630

2007

Volltextzugriff (PDF)

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood, 2021-01, Vol.137 (1), p.49-60

2021

Volltextzugriff (PDF)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

Oncology and therapy, 2020-12, Vol.8 (2), p.311-324

2020

Volltextzugriff (PDF)

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Leukemia & lymphoma, 2017-01, Vol.58 (1), p.145-152

2017

Volltextzugriff (PDF)

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes

Blood, 2002-09, Vol.100 (6), p.2243-2245

2002

Volltextzugriff (PDF)

Multiple Myeloma Presenting as Bilateral Posterior Optic Neuropathy

Neuro-ophthalmology (Amsterdam : Aeolus Press. 1980), 2010-12, Vol.34 (5-6), p.351-355

2010

Volltextzugriff (PDF)

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

British journal of haematology, 2012-11, Vol.159 (4), p.485-488

2012

Volltextzugriff (PDF)

P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S146-S147

2022

Volltextzugriff (PDF)

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Blood, 2018-11, Vol.132 (Supplement 1), p.112-112

2018

Volltextzugriff (PDF)

Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre study

British journal of haematology, 2001-12, Vol.115 (3), p.653-659

2001

Volltextzugriff (PDF)

IgE multiple myeloma: a new case report

Clinical chemistry and laboratory medicine, 2017-02, Vol.55 (2), p.e37-e40

2017

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(77)
Spanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(30)
Female
(25)
Male
(24)
Middle Aged
(24)
Adult
(19)
Aged
(19)
Hematology
(16)
Treatment Outcome
(11)
Biological And Medical Sciences
(10)
Multiple Myeloma
(10)
Adolescent
(9)
Follow-Up Studies
(9)
Oncology
(9)
Acute Lymphoblastic Leukemia
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Prognosis
(8)
Prospective Studies
(8)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Is Early Palliative Care Feasible in Patients With Multiple Myeloma?

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols

Renal involvement in non-malignant IgM gammopathy

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes

Multiple Myeloma Presenting as Bilateral Posterior Optic Neuropathy

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre study

IgE multiple myeloma: a new case report

Suchergebnisse filtern